Answers are grounded in this paper and cite their sources.
Develops a B0AT1 inhibitor to treat phenylketonuria in mice, indicating potential for future therapies.
AT1 and establish a framework for the rational optimization of inhibitors targeting conformationally dynamic allosteric sites in SLC6-family transporters.
No takes yet. Share an insight, caveat, or question.
Imazu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: